The Board of Directors of the association of companies in the biomedical sector in Catalonia, CataloniaBio & HealthTech, in which Lluís Chico from NEOS Surgery held the post of first vice-president and treasurer, has ended its four-year term with a very positive outcome.
The general assembly of members was held on 24 February in Barcelona, where the intensive work performed by the entity between the years 2018 and 2021 was assessed, economic accounts were approved, and posts were then renewed.
“We have gained in visibility and leadership, we have contributed to the sector having experienced a sustained, balanced and solid growth, and we have formulated a strategic plan laying out the path for CataloniaBio & HealthTech of the future,” Jaume Amat, outgoing president of the entity, stated.
In turn, Lluís Chico emphasised that “this development is particularly gratifying because we were presented with the challenge of debuting after the integration of CataloniaBio and HealthTech Cluster. We feel that we are leaving behind a solid legacy to the new board to continue growing organically or with other alliances.”
CataloniaBio & HealthTech is made up of almost 200 enterprises and entities. “We would like to thank our partners for trusting in us and request the greatest possible involvement and participation-based constructive criticism in order to continue consolidating the biomedical industry in Catalonia, which is beyond any doubt extremely valuable to society,” Lluís Chico said to conclude NEOS’ intervention as first vice-president.
We would like to wish the new board, led by Joan Puig de Dou (Kymos) and Mariona Serra (GoodGut of Hipra), the best of luck and success.
First picture: Lluís Chico during the general assembly of members. Second picture, from left to right: general secretary of CataloniaBio & HealthTech, Melqui Calzado, and members of the outgoing board, Albert Giralt (Avinent), Isabel Amat (Reig Jofre), Alfons Nonell (DevsHealth), Carme Lagunas (Ferrer), Lluís Chico (NEOS Surgery), Jaume Amat (Specipig), Judit Anido (Mosaic Biomedicals), Montserrat Vendrell (Alta Life Sciences) and Marta Palicio (Werfen).